Hengrui Pharmaceutical's ophthalmic generics included in the priority review

Hengrui Pharmaceuticals announced yesterday that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd.'s he fluoroproproszolat eye drops were recently included in the list of priority review varieties by the Drug Review Center of the State Drug Administration, with a public notice period of 7 days1The basic situation of drugssecond, drug-related situation
January 10, 2020, the State Drug Administration Drug Review Center to undertake Chengdu Shengdi Pharmaceutical Co., Ltdsubmitted the application for drug registrationHe fluoroproproproproproprosin is a prostaglandin analogue, a selective FP prostaglandin receptor agonist that reduces intra-eye pressure by increasing the amount of water flow ingress of the grape membrane sclorain pathwayUsed to reduce elevated eye pressure in patients with open-angle glaucoma and high eye pressureHis fluoroproproszolat eye drops were first approved for sale in the United States and are now listed in ChinaAt present, the same category of products are Bemeproprosin eye drops (commodity name LUMIGAN), Qufu proprosin (trade name TRAVATAN Z) and lattaprosin (commodity name XALATAN)According to the query, his global sales of fluoroproproszole eye drops in 2019 will be about $185 millionSo far, the company has invested about RMB14.47 million in research and development projects